The MDM2 --p53 feedback loop is crucially important for restricting p53 level and activity during normal cell growth and proliferation, and is thus subjected to dynamic regulation in order for cells to activate p53 upon various stress signals. Several ribosomal proteins, such as RPL11, RPL5, RPL23, RPL26 or RPS7, have been shown to have a role in regulation of this feedback loop in response to ribosomal stress. Here, we identify another ribosomal protein S14, which is highly associated with 5q-syndrome, as a novel activator of p53 by inhibiting MDM2 activity. We found that RPS14, but not RPS19, binds to the central acidic domain of MDM2, similar to RPL5 and RPL23, and inhibits its E3 ubiquitin ligase activity toward p53. This RPS14 --MDM2 binding was induced upon ribosomal stress caused by actinomycin D or mycophenolic acid. Overexpression of RPS14, but not RPS19, elevated p53 level and activity, leading to G1 or G2 arrest. Conversely, knockdown of RPS14 alleviated p53 induction by these two reagents. Interestingly, knockdown of either RPS14 or RPS19 caused a ribosomal stress that led to p53 activation, which was impaired by further knocking down the level of RPL11 or RPL5. Together, our results demonstrate that RPS14 and RPS19 have distinct roles in regulating the MDM2 --p53 feedback loop in response to ribosomal stress.
INTRODUCTION
The tumor suppressor p53 has an essential role in guarding the genome and preventing tumorigenesis by stopping cell proliferation, inducing apoptosis and blocking metastasis mostly via its transcriptional activity. 1, 2 Because of these cytotoxic activities, the oncoprotein MDM2, which is encoded by a transcriptional target gene of p53, 3, 4 is used by cells to monitor p53 functions. MDM2 via its N-terminal domain directly binds to both of the N and C termini of p53 and deactivates this protein by either abrogating its transcriptional activity 5, 6 or ubiquitinating it and mediating its proteasomal turnover. 7 --9 This inhibition of p53 by MDM2 has been gracefully verified by TP53 and mdm2 double-knockout studies. 10, 11 Thus, under stress conditions, multiple cellular mechanisms can be awakened to reactivate p53 by blocking this feedback loop. 12 Recently, an emerging new signaling pathway has been gradually appreciated to untie the MDM2 --p53 loop in response to a type of stress, called ribosomal or nucleolar stress. 13, 14 This stress can be caused by any chemical reagent or genetic, molecular and cellular events that disrupt each step of ribosomal biogenesis. These reagents and events include treatment of cells with low dose of actinomycin D, 15 5 --fluorouracil 16, 17 or mycophenolic acid, 18 serum starvation or contact inhibition, 19 impairment of 40S or 60S ribosomal biogenesis by knockdown of either ribosomal protein (RP) S6 20 or RPL29 and RPL30, 21 defects in 18S or 28S RNA processing, 22 malfunction of nucleolar proteins, such as Bop1, 23 involved in ribosome biogenesis, inhibition of B23 (also known as nucleophosmin) activity by ARF, 24 which is encoded by an alternate reading frame of the INK4a/ARF locus (CDKN2A) or ablation of nucleostemin by siRNAs, 25 and knockdown of PAK1IP1, a nucleolar protein important for rRNA processing. 26 Interestingly, it has been recently shown that ribosomal stress can also be induced by genotoxic insults, such as cisplatin or UV irradiation, probably through degradation of RPL37. 27 Upon ribosomal stress, several RPs, such as RPL11, 19,28 --30 38 associate with MDM2 and inhibit MDM2-mediated ubiquitination and degradation of p53. Furthermore, the MDM2 C305F , which is defective in RPL11 and RPL5 binding in vitro 39 and in vivo, 40 has been shown to impair the p53 response to ribosomal stress in animals, 40 strongly demonstrating the essential role of RP --MDM2 interactions in the activation of p53 upon ribosomal stress.
The ribosomal stress--p53 pathway is also possibly linked with the pathogenesis of some human genetic diseases, such as myelodysplastic syndrome. 41 For instance, mutations of RPS19 are associated with Diamond--Blackfan anemia (DBA), 42 a congenital erythroblastopenia with strikingly absent or decreased erythroid precursors. In addition, deletion of one allele of another RP-encoding gene, RPS14, results in 5q-syndrome with a characteristic defect in erythroid differentiation. 43 In line with these human genetic studies, RPS14 haploinsufficiency in mice also led to a 5q-syndrome-like phenotype with bone marrow disorders, which can be completely rescued by further deleting TP53 in the animals, 44 suggesting that p53 has a role in the pathogenesis of this subtype of myelodysplastic syndrome. 41, 44 Recently, mutations of several MDM2-binding RPs, such as RPL5, RPL11 45, 46 or RPS7, 45 have also been found in DBA patients. These studies prompted us to explore whether DBA-associated RPS19 or 5q-syndrome-associated RPS14 may have a role in regulating the MDM2--p53 feedback loop as well.
In this study, we reveal differential regulation of this feedback loop by RPS14 and RPS19. RPS14, but not RPS19, interacted with MDM2, inhibited MDM2-mediated ubiquitination and degradation of p53 and induced p53-dependent cell cycle arrest in response to ribosomal stress.
RESULTS

RPS14 interacts with MDM2 in cells and in vitro
The fact that mutations of the MDM2-interacting RPL11, RPL5 and RPS7 have recently been shown to be associated with DBA 45, 46 hints that DBA-linked RPS19 and 5q-syndrome-associated RPS14 might also interact with MDM2. To test this idea, we first introduced ectopic Flag-RPS14 or Flag-RPS19 alone or together with HA-MDM2 into 293 cells and then performed a set of reciprocal co-immunoprecipitation (IP) --immunoblot (IB) assays. Interestingly, we found that only Flag-RPS14, but not Flag-RPS19, could be co-immunoprecipitated with HA-MDM2 in these co-IP --IB assays (Figures 1a and b) . Consistent with these results, endogenous RPS14 also bound to endogenous MDM2 in response to ribosomal stress caused by actinomycin D treatment of HCT116 cells (Figure 1c) . These results indicate that RPS14, but not RPS19, can associate with MDM2 in cells, as well upon ribosomal stress. In addition, nucleolar RPS14 molecules were released to the nucleoplasm upon ribosomal stress (Supplementary Figure S1) , which probably favored the interaction of RPS14 with MDM2, as MDM2 mainly localized in the nucleoplasm (Supplementary Figure  S1) . Although it has been reported that ribosomal proteins, L5, L11 and L23, selectively bind to MDM2, but not MDMX, 16 we wondered whether RPS14 associates with MDMX. To test this idea, ectopic Myc-MDMX was introduced into H1299 cells alone or together with Flag-RPS14 or Flag-RPL11. As shown in Figure 1d , similar to RPL11, RPS14 did not bind to MDMX.
As other 40S subunits, such as RPS7, 35, 36 RPS3, 47 RPS27 37 and RPS27a, 38 have been reported to bind to MDM2, the association of RPS14 with MDM2 in cells might be indirect via these known MDM2-binding RPs. To determine whether RPS14 directly binds to MDM2 and, if so, to which domain of MDM2 it binds, we conducted a set of GST fusion protein association assays by using His-RPS14 and GST-MDM2 deletion fusion proteins purified from bacteria ( Figure 2a) . GST-MDM2, but not GST alone, interacted with His-RPS14 directly. We also found that His-RPS14 bound to residues 1 --301, but not 1 --151, 285 --340 or 294 --491, of MDM2. This result indicates that, similar to RPL5, 31 RPS14 also directly contacts the central acidic domain of MDM2 (Figure 2d ), which was confirmed by co-IP --IB assays following introduction of Flag-RPS14 and V5-MDM2 fragments into 293 cells (Figure 2b) .
To test whether RPS14 competes with RPL5 or RPL23 for association with MDM2, we introduced combinations of ectopic HA-MDM2, Flag-RPL5, pEGFP-RPL23 or Flag-RPS14 into H1299 cells. As shown in Supplementary Figure S2, RPS14 slightly reduced the level of the RPL5--MDM2 interaction, because both RPs bound to the same central acidic domain of MDM2. However, the RPL23--MDM2 interaction was not affected by overexpressing RPS14, as RPL23 preferentially bound to the C-terminal acidic domain of MDM2. . 28,31 --36,47 To test whether RPS14 would also do so, we introduced combinations of His-Ub, p53, HA-MDM2 and Flag-RPS14 plasmids into H1299 cells to test p53 ubiquitination in the cells. As shown in Figure 3a , MDM2 ubiquitinated p53, whereas ectopic Flag-RPS14 inhibited this ubiquitination in a dosedependent manner. This inhibition was not due to variation of sample loading, as the p53 level in each lane was approximately equivalent (middle panel of Figure 3a ). Consistent with this result, Flag-RPS14 overcame the MDM2-mediated degradation of exogenous p53 in H1299 cells (Figure 3b ), as well as of endogenous p53, and induced p53 activity in a dose-dependent manner in A549 cells (Figure 3c ). Also Flag-RPS14 markedly extended the half-life of endogenous p53 (Figures 3e and f) . By contrast, overexpression of Flag-RPS19 did not show any significant effect on p53 level and activity in A549 cells (Figure 3d ), which is consistent with the results of Figures 1a and b. These results indicate that RPS14, but not RPS19, alleviates MDM2-mediated p53 ubiquitination and degradation, leading to p53 activation. This effect was perhaps through direct binding of RPS14 to MDM2, as overexpression of wild-type RPS14 induced p53 and p21 levels more markedly than its N-terminal or C-terminal fragment (Figure 3g ), which was with a reduced ability to bind to MDM2 (Figure 2c ). In addition to p21, another p53 target, Bax, which is involved in the apoptotic pathway, was also slightly induced by overexpressing RPS14 (Figure 3h) . However, the level of an apoptosis indicator, cleaved PARP, was not elevated, probably because the free forms of ribosomal proteins, such as extra-RPS14 molecules, would only cause modest stress (ribosomal stress), which might not need to induce apoptosis as a terminating outcome. Although it has been well documented that RPs activate p53 by inhibiting the E3 ligase activity of MDM2, we wondered whether RPS14 could interrupt the MDM2 --p53 interaction. We tested this idea by performing a set of protein --protein binding competition assays using both cell-based and in vitro systems with purified proteins. As shown in Supplementary Figure S3 , RPS14 had no effect on the MDM2 --p53 interaction in cells by co-IP --IB assays (Supplementary Figure S3A) or in vitro by GST pull-down assays (Supplementary Figure S3B) . These results suggest that RPS14 can lead to p53 stabilization by inhibiting MDM2-mediated p53 ubiquitination without interfering with the MDM2 --p53 interaction.
Ectopic expression of RPS14 induces p53-dependent cell cycle arrest and growth inhibition Previous studies by us 31, 32 and others 28, 33 have shown that overexpression of RPL11, RPL5 or RPL23 inhibits p53-dependent cell proliferation through induction of p21. Although RPS14 also induced p21 via p53 (Figure 3c ), we tested whether RPS14 has a similar effect on cell growth. To do so, we introduced pcDNA or Flag-RPS14 plasmids into A549 or H1299 cells and performed Fluorescence-activated cell sorter analysis. As shown in Figure 4 , ectopic expression of RPS14 significantly inhibited the cell cycle progression at both G 1 and G 2 phases in A549 cells (Figure 4a ), whereas overexpression of RPS14 in p53-deficient H1299 cells had no effect on the cell cycle progression (Figure 4b ). The same experiments were performed using HCT116 cells harboring wildtype or null p53, except for using pEGFP-RPS14 and pEGFP empty vector as a control (Figures 4c and d) . Interestingly, overexpression of RPS14 induced G2 arrest in this colon cancer cell line in a p53-dependent manner (Figures 4c and d) . Consistent with the above results, RPS14 also inhibited cell proliferation as measured by BrdU incorporation assays (Figure 4e) . To test the effect of ectopically expressed RPS14 on cell growth, we conducted cell viability assays using cell counting kit-8 (CCK-8). Cells were seeded into 96-well plates at 24-h post transfection, and the absorbance at 450 nm was measured every 24 h. As shown in Figure 4f , RPS14 markedly suppressed cell growth in A549 cells during the 5-day-long culture. Interestingly, RPS14 also moderately suppressed cell growth in p53-deficient H1299 cells (Figure 4g ), which might be due to the inhibition of c-Myc by RPS14 (data not shown). These results indicate that overexpression of RPS14 can indeed induce p53-dependent cell cycle arrest and consequently inhibit cell proliferation.
Ablation of endogenous RPS14 by siRNAs impairs ribosomal stress-triggered p53 activation, although it induces p53 as well To demonstrate the physiological impact of endogenous RPS14 on the ribosomal stress-p53 pathway, we used siRNAs to knock down endogenous RPS14. As shown in Figures 5a and b , knockdown of RPS14 in HCT116 or A549 cells induced p53 compared with the scrambled siRNA control, as expected. 41, 44 Consistently, depletion of RPS14 caused p53-dependent G2 arrest in HCT116 cells (Figures 5e and f) . Nevertheless, although cells were under ribosomal stress, such as treatment with 5 nM actinomycin D (Figure 5a ) or 10 mM mycophenolic acid (Figure 5b ), the reduction of RPS14 by siRNAs partially lessened the induction of p53 by these reagents as reflected in the decrease of the p53 level and activity (as measured by MDM2 level). These results clearly demonstrate that the ribosomal stresscaused p53 activation in part requires RPS14 in cells.
To test whether this requirement of RPS14 for p53 activation is only responsive to ribosomal stress, we conducted the same experiments as shown in Figures 5a and b , except for using Doxorubicin as a DNA-damage inducer. Interestingly, ablation of RPS14 impaired the induction of MDM2, although it failed to affect p53, in response to DNA-damage stress (Supplementary Figure S4) . Furthermore, we found that the half-life of MDM2 upon both ribosomal stress and DNA damage decreased in response to RPS14 ablation regardless of whether p53 half-life reduced or not (Supplementary Figure S5) . Finally, overexpression of RPS14 in p53-null H1299 cells led to the increase of MDM2 levels in a dosedependent manner, but independently of p53 (Supplementary Figure S6A) , and this increase was not at RNA levels (data not shown). The induction of MDM2 levels was also reported when RPS7 36 or RPL11 48 was overexpressed. However, overexpression of RPS14, similar to RPL11, 48 resulted in the accumulation of Figure S6B) , suggesting that RPS14 may regulate MDM2 stability via a postubiquitination mechanism similar to that of RPL11. 48 Together with the above results (Figures 1--5 and Supplementary Figure S1 -S6), these data suggest that RPS14 regulates the stability of p53 and MDM2 through distinct mechanisms.
Ablation of endogenous RPS14 or RPS19 results in RPL5-and RPL11-dependent p53 activation The RPS19 gene is one of the most mutated RP genes in DBA patients with the defect in erythroid differentiation 42 analogous to 5q-syndrome patients with RPS14 haploinsufficiency. 41 The p53 activation has been associated with these ribosomopathies. 41 In addition, the results of Figures 5a and b showed that knockdown of RPS14 indeed induced p53 in cells. It is likely that haploinsufficiency of each of the RPs might give rise to ribosomal stress and activate p53 through an RPL5-and/or RPL11-dependent mechanism. To test this idea, we performed siRNA-mediated ablation of RPS14 or RPS19. Indeed, reduction of either RPS14 or RPS19 by siRNAs activated p53 and increased the level of the p53 targets, p21 and MDM2 (Figures 5c and d, lane 1 and 2 ). Further knockdown of RPL5 or RPL11 by siRNAs markedly inhibited the p53 level that was induced by RPS14 or RPS19 knockdown (Figures 5c and d, lane 3 and 4) . These results show that p53 activation induced by knockdown of RPS14 or RPS19 requires RPL5 and RPL11, which is in accordance with recent reports. 20, 21 DISCUSSION Several RPs have been recently identified as critical regulators of this MDM2-p53 loop in response to ribosomal stress. Here we reveal RPS14, which is highly associated with 5q-syndrome, 43, 44 as another novel player of this ribosomal stress-p53 pathway. Supporting this statement are several lines of evidence. First, RPS14 directly interacted with MDM2 in cells and in vitro via the central acidic domain of MDM2 (Figures 1 and 2) . Moreover, similar to RPL5, 31 it inhibited MDM2-mediated p53 ubiquitination and degradation, extending the half-life of p53 (Figure 3 ). In addition, RPS14 induced p53-dependent G 1 and G 2 arrest (Figure 4) . Conversely, ablation of RPS14 by siRNAs hampered the p53 activation induced by ribosomal stress (Figures 5a and b but not DNA damage (Supplementary Figure S4) . These results clearly demonstrate that RPS14 is a new player of the ribosomal stress-p53 pathway.
However, interestingly, knockdown of RPS14 also led to p53 activation (Figures 5a and b) , similar to the case of RPL23. 32, 33 This p53 activation was RPL5 and RPL11 dependent (Figure 5c ), which is consistent with a recent study in human blood cells. 49 Although overexpression of RPS19 did not affect p53 (Figures 1 and 3) , its knockdown, similar to RPS14 knockdown, also activated p53 dependently of RPL11 and RPL5 (Figure 5d ). These results, together with the studies by others, 20, 49 suggest a testable model in the future, that is, reducing the level of each of these 40S subunits may cause p53-activating ribosomal stress by interfering with the 40S assembly.
Identification of RPS14 as another MDM2 suppressor, in addition to more than half a dozen of previously and recently reported MDM2 regulators as aforementioned, in response to ribosomal stress, raises one simple question. Why would mammalian cells need so many RPs to overcome the negation of p53 by MDM2? One possibility would be that MDM2 might work as a multiple subunit complex, such as a homohexamer, 50, 51 to inactivate p53 in cells. Thus, individual RPs would need to work together as a sub-ribosomal complex or to independently bind to different MDM2 molecules in the homohexameric complex in order to efficiently inactivate MDM2 and consequently activate p53 (Figure 5g) . Alternatively, different MDM2-binding RPs may act at different time points in a sequential manner to inactivate MDM2 upon ribosomal stress, depending on which RP is released early post stress. In addition, different ribosomal stress signals may use different MDM2-binding RPs to inhibit MDM2. For example, as aforementioned (Figures 5c, d and g ), RPS14 knockdown induced p53 by using RPL11 and RPL5 to inactivate MDM2, as RPS14 would not be available in this case (Figure 5g) . 20 Interestingly, impairing the 60S biogenesis by knocking down RPL30 and RPL29 also required RPL11 and RPL5 for p53 activation. 21 As the cancerderived mutation C305F in the zinc-finger domain of MDM2, which disrupted RPL11-and RPL5-MDM2 but not RPL23 --MDM2 interaction, attenuated the p53 activation induced by Act. D, 5-FU and MPA in vivo, 40 it is likely that RPL11 and RPL5 may have a central role in the choreographic formation of the MDM2-interacting sub-ribosomal complex in response to ribosomal stress.
However, most of the known MDM2-binding RPs bind to the central acidic domain of MDM2 except RPL11. 31 --35,52 This highlights the importance of this domain, in addition to zincfinger domain, of MDM2 in sensing ribosomal stress. It remains to be investigated whether any modifications or mutations in this acidic domain might affect the binding of specific RPs to MDM2. Multiple sites of the central acidic domain of MDM2 have been shown to be phosphorylated by casein kinase I in response to genotoxic stresses, 53 leading to enhanced binding of SCF bÀTRCP E3 ligase 53 to MDM2. As previously reported, multiple genotoxic insults could also cause ribosomal stress; 14 hence, would the modifications influence the interaction between RPs and MDM2? Inversely, would the binding of RPs to the central domain of MDM2 interfere with the binding of SCF bÀTRCP E3 ligase to MDM2, leading to stabilization of MDM2? 53 In addition, it has been shown that ribosomal stress elevated p53 acetylation levels; 54 thus, it remains to be tested whether MDM2 could be acetylated under ribosomal stress and, if so, would acetylated MDM2 affect the RP --MDM2 interactions. Recently, neddylation of RPL11 was shown to regulate RPL11 stability and its ability to activate p53 in response to ribosomal stress. 55 Nevertheless, it remains elusive whether RPs could be phosphorylated or acetylated and, if so, whether these modifications would affect their ability to activate p53. By contrast, RPL26 or RPS7 was reported to be ubiquitinated by MDM2 for degradation. 36, 52 Finally, it would be interesting to see whether mutations in the central acidic domain of MDM2, which might disrupt the RP-MDM2 interactions, could be identified in human cancers. It is noteworthy that RPS14, similar to RPL11 48 and RPS7, 36 could also induce the protein level of MDM2 via a postubiquitination mechanism independently of p53 ( Supplementary  Figures S4-S6 ). This finding implies that these RPs might block the recruitment of MDM2 to the 26S proteosomal machinery by interfering with the interaction of MDM2 with the lid subunits, such as S2, 56 of the 26S proteasome. These are enticing questions for future studies.
MATERIALS AND METHODS
Cell lines, plasmids and antibodies
Human 293, H1299, A549 and HCT116 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 50 U/ml penicillin and 0.1 mg/ml streptomycin at 37 1C in a 5% CO 2 humidified atmosphere. Flag-tagged RPS14 and RPS19 expression plasmids were generated by inserting the full-length cDNAs amplified by RT --PCR from HCT116 cells into the pcDNA3-2Flag vectors. The following primers were used---P1: 5 0 -CGCGGATCCATGGCACCTCGAAAGGGGA-3 0 and P2: 5 0 -CCGGAATTCTCACAGACGGCGACCACGGCGA-3 0 for RPS14, P3: 5 0 CGCGGATCCATGCCTGGAGTTACTGTAA 3 0 and P4: 5 0 -CCGGAATTCCT AATGCTTCTTGTTGGCAGCT-3 0 for RPS19. The His-tagged RPS14 plasmid for bacterial expression was generated by engineering the RPS14 full-length cDNAs from pcDNA3-2Flag-RPS14 to the pET-30a vector using BamHI and EcoRI restriction sites. A set of Flag-tagged deletion mutant RPS14 expression plasmids were generated by inserting the nucleotides 1 --150 or 151 --453 of full-length cDNAs into the pcDNA3 --2Flag vectors. The following primers were used---P1 and P5: 5 0 -CCGGAATTCTCACTTGCCAG AAAGATCAGTGA-3 0 for RPS14/1 --50; P6: 5 0 -CGCGGATCCGAAACCATCT GCCGTGTGAC-3 0 and P2 for RPS14/51 --151. EGFP-tagged RPS14 was generated using the following primers---P7: 5 0 -CCGGAATTCTATGGCACCTCG AAAGGGGA-3 0 and P8: 5 0 -CGCGGATCCTCACAGACGGCGACCACGGCGA-3 0 . Flag-RPL5, Flag-RPL11 pEGFP-RPL23, HA-MDM2, GST-MDM2, deletion mutants of GST-MDM2 and V5-MDM2, Myc-MDMX, His-Ub, p53 pEGFPp53 and GST-p53-coding plasmids have been described previously. 31, 32 Anti-L5, 31 anti-L11, 57 anti-HA (12CA5),anti-MDM2 (2A10 and 4B11) 31, 32 and anti-MDMX (8C6) 56 
GST fusion protein association assay
His-tagged RPS14 proteins were expressed in E. coli, puried through a Ni-NTA (QIAGEN, Valencia, CA, USA) column and eluted with 0.5 M imidazole. Protein --protein interaction assays were performed as described previously by using fusion protein-containing glutathione beads. 58 Puried His-tagged RPS14 proteins were incubated with the glutathione-sepharose 4B beads (Sigma-Aldrich) containing 500 ng of GST-MDM2/1 --491, GST-MDM2/1 --151, GST-MDM2/1 --301, GST-MDM2/285 --340, GST-MDM2/294 --491 or GST. At 30 min after incubation at room temperature, the mixtures were washed twice in lysis buffer containing 10% glycerol and once in SNNTE buffer. Bound proteins were analyzed on a 15% SDS gel and detected by IB with the anti-RPS14 polyclonal antibody.
Transient transfection, IB and co-IP analyses
Cells were transfected with plasmids as indicated in figure legends using TransFectin lipid reagent following the manufacturer's protocol (Bio-Rad, Hercules, CA, USA). The cells were harvested at 30 --48 h post transfection and lysed in lysis buffer consisting of 50 mM Tris/HCl (pH 8.0), 0.5% Nonidet P-40 (NP-40), 1 mM EDTA, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 mM, 0.25 mg/ml pepstatin A and 1 mM leupeptin. Equal amounts of clear cell lysate (20 --50 mg) were used for IB analysis as described Activation of p53 via RPS14 X Zhou et al previously. 59 IP was conducted using antibodies as indicated in the figure legends and described previously. 60 Beads were washed twice with lysis buffer, and once with SNNTE buffer (50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 1% Nonidet P-40, 500 mM NaCl and 5% sucrose). Bound proteins were detected by IB with antibodies as indicated in the figure legends.
In vivo ubiquitination assay H1299 cells were transfected with His-Ub (1.5 mg), p53 (0.5 mg), HA-MDM2 (1 mg) or Flag-RPS14 expression plasmids as indicated in Figure 3 . At 48 h after transfection, cells were harvested and split into two aliquots, one for IB and the other for ubiquitination assays. In vivo ubiquitination assays were conducted as previously described. 32 Eluted proteins were analyzed by IB with monoclonal p53 antibodies.
Cell cycle analysis
Cells transfected with pcDNA, Flag-RPS14, pEGFP, pEGFP-RPS14, scrambled siRNAs or RPS14 siRNAs as indicated in the figure were fixed and stained in 500 ml of propidium iodide (PI, Sigma-Aldrich) stain buffer (50 mg/ml PI, 200 mg/ml RNase A, 0.1%. Triton X-100 in phosphate-buffered saline) at 37 1C for 30 min. The cells were then analyzed for DNA content using a BD Biosciences FACScan flow cytometer. Data were analyzed using the CellQuest and Modfit software programs.
BrdU incorporation assay
BrdU incorporation assays were performed as described previously. 57 Cells were incubated in the presence of 10 mM of BrdU for 5 h. Cells were then fixed with 95% ethanol and 5% acetic acid, treated with 2 M HCl containing 1% Triton X-100 and stained with the monoclonal anti-BrdU antibody (Santa Cruz Biotechnology), followed by staining with Alexa Fluor 546 (red) goat anti-mouse antibodies and DAPI. Stained cells were analyzed under a Zeiss Axiovert 25 uorescent microscope.
Cell viability assay
To assess the long-term cell growth, the cell counting kit-8 (CCK-8) (Dojindo Molecular Technologies Inc., Gaithersburg, MD, USA) was used according to the manufacturer's instructions. Cell suspensions were seeded at 3000 cells per well in 96-well culture plates at 24 h post transfection. Cell growth inhibition was determined by adding WST-8 at a final concentration of 10% to each well, and the absorbance of the samples was measured at 450 nm using SpectraMax M5e microplate reader (Molecular Device, Sunnyvale, CA, USA) after culture for 5 days.
